- Home
- ARMP vs RENB Comparison
ARMP vs RENB Comparison
Compare ARMP & RENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- RENB
- Stock Information
- Founded
- ARMP N/A
- RENB 2011
- Country
- ARMP United States
- RENB United States
- Employees
- ARMP N/A
- RENB N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- RENB Biotechnology: Pharmaceutical Preparations
- Sector
- ARMP Health Care
- RENB Health Care
- Exchange
- ARMP Nasdaq
- RENB Nasdaq
- Market Cap
- ARMP 52.1M
- RENB 62.0M
- IPO Year
- ARMP N/A
- RENB N/A
- Fundamental
- Price
- ARMP $2.22
- RENB $0.27
- Analyst Decision
- ARMP Strong Buy
- RENB
- Analyst Count
- ARMP 1
- RENB 0
- Target Price
- ARMP $9.00
- RENB N/A
- AVG Volume (30 Days)
- ARMP 18.4K
- RENB 2.2M
- Earning Date
- ARMP 08-12-2025
- RENB 05-15-2025
- Dividend Yield
- ARMP N/A
- RENB N/A
- EPS Growth
- ARMP N/A
- RENB N/A
- EPS
- ARMP N/A
- RENB N/A
- Revenue
- ARMP $4,699,000.00
- RENB N/A
- Revenue This Year
- ARMP $8.43
- RENB N/A
- Revenue Next Year
- ARMP N/A
- RENB N/A
- P/E Ratio
- ARMP N/A
- RENB N/A
- Revenue Growth
- ARMP 14.24
- RENB N/A
- 52 Week Low
- ARMP $0.90
- RENB $0.26
- 52 Week High
- ARMP $3.42
- RENB $2.10
- Technical
- Relative Strength Index (RSI)
- ARMP 63.56
- RENB 38.03
- Support Level
- ARMP $1.93
- RENB $0.33
- Resistance Level
- ARMP $2.24
- RENB $0.32
- Average True Range (ATR)
- ARMP 0.16
- RENB 0.03
- MACD
- ARMP 0.03
- RENB -0.00
- Stochastic Oscillator
- ARMP 104.55
- RENB 4.84
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.